This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- The heparin frequently given before percutaneous coronary intervention (PCI) should be pushed to as early as possible in patients with ST-segment elevation myocardial infarction (STEMI), according to findings from the Chinese.
A study revealed using language models as diagnostic aids did not significantly enhance clinical reasoning or accuracy among physicians over conventional resources alone.
(MedPage Today) -- SAN DIEGO -- Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed. Among 101 patients, those who received 2.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
(MedPage Today) -- A Chinese study suggested that cold weather may make people more susceptible to myocardial infarction with non-obstructive coronary arteries compared with myocardial infarction from obstructive disease. (European Heart Journal.
Until now, patients with aortic stenosis—a narrowing of one of the heart's main valves—have had to wait until symptoms become severe before undergoing valve replacement. Findings from the EVOLVED study, however, indicate that patients can avoid symptoms such as chest pain, dizziness and fainting if surgery is performed at an earlier stage of the condition.
The goal of the CLEAR SYNERGY OASIS 9 trial was to determine the long-term cardiovascular (CV) effects of colchicine following percutaneous coronary intervention (PCI) for ST-segment elevation or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively).
The goal of the CLEAR SYNERGY OASIS 9 trial was to determine the long-term cardiovascular (CV) effects of colchicine following percutaneous coronary intervention (PCI) for ST-segment elevation or large non–ST-segment elevation myocardial infarction (STEMI or NSTEMI, respectively).
A team of researchers have worked together to identify possible genes associated with certain metabolites—molecules involved in the body's biochemical processes—and cardiovascular risk.
Yale New Haven (Conn.) Health and the Yale School of Medicine have appointed Marc Pelletier, MD, division chief of cardiac surgery for the department of surgery and section chief of cardiac surgery at Yale New Haven Hospital as well as physician-in-chief of cardiac surgery for the health system's Heart and Vascular Center.
Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, myocardial infarction, stroke or ischemia-driven revascularization.
In this interview, Drs. Allen Taylor and Derek Chew discuss the findings of the RAPIDxAI trial: re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting evidence to practice using AI.
At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.
What is the ability of a systolic blood pressure (SBP) polygenic risk score (PRS) to predict antihypertensive treatment (AHT) response and apparent treatment-resistant hypertension (aTRH)?
A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.
While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based on geographic region.
Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has i.
The goal of the ECLIPSE trial was to evaluate orbital atherectomy prior to drug-eluting stent (DES) implantation compared with conventional percutaneous coronary intervention (PCI) without atherectomy among patients with calcified coronary lesions.
This study was released in NEJM without much fanfare at the fag end of the last century, (rather the millennium) in 1999. Dr. Bertram Pitt and his team scripted this from the Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA. One can’t expect even in your dreams a study like this would be be done in the future. This study tested PTCA vs with a single lipid lowering drug in terms of plaque regression.
Sirolimus-coated balloons were noninferior to paclitaxel-coated balloons in terms of safety and efficacy in treating patients with femoropopliteal artery disease, based on findings from the head-to-head.
The routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions.
Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.
(MedPage Today) -- SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During a median 2 years of post.
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
Circulation: Genomic and Precision Medicine, Volume 17, Issue 6 , Page e004464, December 1, 2024. BACKGROUND:Interpretation of variants of uncertain significance (VUSs) remains a challenge in the care of patients with inherited cardiovascular diseases (CVDs); 56% of variants within CVD risk genes are VUS, and machine learning algorithms trained upon large data resources can stratify VUS into higher versus lower probability of contributing to a CVD phenotype.METHODS:We used ClinVar pathogenic/lik
Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content